161 related articles for article (PubMed ID: 5406056)
1. [Behavior in vivo of strains of Pasteurella pestis in relation to their efficacy as live vaccines].
Markenson J; Ben-Efraim S
Ann Inst Pasteur (Paris); 1969 Aug; 117(2):196-212. PubMed ID: 5406056
[No Abstract] [Full Text] [Related]
2. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.
Feodorova VA; Pan'kina LN; Savostina EP; Sayapina LV; Motin VL; Dentovskaya SV; Shaikhutdinova RZ; Ivanov SA; Lindner B; Kondakova AN; Bystrova OV; Kocharova NA; Senchenkova SN; Holst O; Pier GB; Knirel YA; Anisimov AP
Vaccine; 2007 Nov; 25(44):7620-8. PubMed ID: 17913308
[TBL] [Abstract][Full Text] [Related]
3. Potency of killed plague vaccines prepared from avirulent Yersinia pestis.
Williams JE; Altieri PL; Berman S; Lowenthal JP; Cavanaugh DC
Bull World Health Organ; 1980; 58(5):753-6. PubMed ID: 6975184
[TBL] [Abstract][Full Text] [Related]
4. Hereditary hemochromatosis restores the virulence of plague vaccine strains.
Quenee LE; Hermanas TM; Ciletti N; Louvel H; Miller NC; Elli D; Blaylock B; Mitchell A; Schroeder J; Krausz T; Kanabrocki J; Schneewind O
J Infect Dis; 2012 Oct; 206(7):1050-8. PubMed ID: 22896664
[TBL] [Abstract][Full Text] [Related]
5. A dam mutant of Yersinia pestis is attenuated and induces protection against plague.
Robinson VL; Oyston PC; Titball RW
FEMS Microbiol Lett; 2005 Nov; 252(2):251-6. PubMed ID: 16188402
[TBL] [Abstract][Full Text] [Related]
6. Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine.
Griffin K; Bedford R; Townson K; Phillpotts R; Funnell S; Morton M; Williamson D; Titball R
FEMS Immunol Med Microbiol; 2005 Mar; 43(3):425-30. PubMed ID: 15708318
[TBL] [Abstract][Full Text] [Related]
7. Application of the antibody neutralization reaction in differential diagnosis of the etiologic agent of plague and the study of mutual relations between the amount of fraction I and virulence in strains of the plague microbe (Pasteurella pestis).
Timofeeva LA; Aparin GP
J Hyg Epidemiol Microbiol Immunol; 1968; 12(4):420-5. PubMed ID: 5752128
[No Abstract] [Full Text] [Related]
8. Immunogenicity of plague vaccines in mice and guinea pigs.
von Metz E; Eisler DM; Hottle GA
Appl Microbiol; 1971 Jul; 22(1):84-8. PubMed ID: 5111306
[TBL] [Abstract][Full Text] [Related]
9. Expression of Yersinia pestis V antigen in attenuated salmonella typhimurium: development of a novel vaccine for plague.
Leary SE; Eley SM; Williamson ED; Titball RW
Contrib Microbiol Immunol; 1995; 13():216-7. PubMed ID: 8833838
[No Abstract] [Full Text] [Related]
10. [Early protection of animals, immunized by a recombinant plague vaccine, from experimental plague].
Gremiakova TA; Amel'chenko VA; Anisimov GA
Biull Eksp Biol Med; 1995 Jan; 119(1):54-7. PubMed ID: 7718805
[No Abstract] [Full Text] [Related]
11. A plague upon the phagocytes.
DeLeo FR; Hinnebusch BJ
Nat Med; 2005 Sep; 11(9):927-8. PubMed ID: 16145573
[No Abstract] [Full Text] [Related]
12. [Plague and its agents (current state of our knowledge)].
Knapp W
Cah Med; 1970 Jul; 11(9):779-86. PubMed ID: 4989215
[No Abstract] [Full Text] [Related]
13. Plague.
Henderson RJ
Trop Dis Bull; 1969 Jul; 66(7):653-9. PubMed ID: 4896220
[No Abstract] [Full Text] [Related]
14. Deadly plague versus mild-mannered TLR4.
Dziarski R
Nat Immunol; 2006 Oct; 7(10):1017-9. PubMed ID: 16985495
[No Abstract] [Full Text] [Related]
15. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response.
Montminy SW; Khan N; McGrath S; Walkowicz MJ; Sharp F; Conlon JE; Fukase K; Kusumoto S; Sweet C; Miyake K; Akira S; Cotter RJ; Goguen JD; Lien E
Nat Immunol; 2006 Oct; 7(10):1066-73. PubMed ID: 16980981
[TBL] [Abstract][Full Text] [Related]
16. [Morphological study of the damaging effect of an EB vaccine strain of the plague microbe in inbred mice].
Nazarova LS; Isupov IV; Pavlova LP; Gor'kova AV; Dushkin VA
Biull Eksp Biol Med; 1988 Jun; 105(6):761-4. PubMed ID: 3390604
[TBL] [Abstract][Full Text] [Related]
17. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
18. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
Palin A; Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
Vaccine; 2007 Jan; 25(4):741-50. PubMed ID: 16959385
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
[TBL] [Abstract][Full Text] [Related]
20. Pathogenicity and immunogenic efficacy of a live attentuated plaque vaccine in vervet monkeys.
Hallett AF; Isaäcson M; Meyer KF
Infect Immun; 1973 Dec; 8(6):876-81. PubMed ID: 4206343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
